Molnupiravir and Favipiravir for COVID-19 Treatment Molnupiravir is an experimental anti-viral drug used for the treatment of influenza. Similarly, Favipiravir is an anti-viral drug which is also used for the treatment of influenza in Japan. The former orally bioavailable nucleoside and latter pyrazinecarboxamide are reported as potential candidate for treatment of COVID-19. The mechanism of action of Molnupivir against COVID-19 is producing copying errors when SARS-CoV-2 undergoes viral replication. The mechanism of action of Favipiravir against COVID-19 is inhibiting RNA-polymerase which is the most important enzyme for viral replication. Favipiravir is recommended for use against COVID-19 in Russia. Currently, several clinical trials are being conducted to conclude the efficacy of Favipiravir and Molnupivir.